tradingkey.logo

Medical diagnostics firm Biomerica's Q2 revenue falls amid product transition

ReutersJan 14, 2026 10:30 PM


Overview

  • Medical diagnostics firm's Q2 revenue fell yr/yr due to absence of large distributor orders

  • Net loss for Q2 widened to $1.32 mln from $0.95 mln last year

  • Company entered marketing agreement with Henry Schein for inFoods IBS test


Outlook

  • Biomerica sees incremental revenue from inFoods IBS and new partnerships driving margin expansion

  • Company expects Medicare payment rate to expand patient access to inFoods IBS

  • Biomerica plans to leverage regulatory approval in Egypt for international expansion


Result Drivers

  • PRODUCT TRANSITION - Biomerica is shifting focus from lower-margin products to higher-margin diagnostic-guided therapy products, impacting current revenue

  • MENA REGION ORDERS - Revenue decline attributed to absence of large initial distributor orders in MENA region

  • COST MANAGEMENT - Operating expenses decreased by 4% year-to-date due to cost discipline and operational efficiency


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

$1.21 mln

Q2 Net Income

-$1.32 mln

Q2 Gross Margin

4.00%

Q2 Operating Expenses

$1.42 mln

Q2 Operating Income

-$1.37 mln

Press Release: ID:nGNX2y46Vp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI